Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.
$SYRE
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2025 | $43.00 | Buy | Deutsche Bank |
| 4/8/2025 | $45.00 | Outperform | Leerink Partners |
| 3/18/2025 | $27.00 | Outperform | Wolfe Research |
| 9/4/2024 | $45.00 | Outperform | Wedbush |
| 7/16/2024 | Outperform | Evercore ISI | |
| 5/2/2024 | $50.00 | Outperform | Robert W. Baird |
| 3/1/2024 | $12.00 → $35.00 | Equal Weight → Overweight | Wells Fargo |
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
Deutsche Bank initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $43.00
Leerink Partners initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00
Wolfe Research initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $27.00
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,300 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on December 1, 2
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 19,600 shares of common stock of Spyre to one non-executive employee as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on November 3, 2025 and w
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened balance sheet with $316 million gross proceeds from an underwritten public offering of common stock $783 million of pro forma cash, cash equivalents, and marketable securities
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass., June 1
WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-pres
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 (longest follow-up available for pharmacodynamic data) Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, follow
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini
WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)